Get the Stockscreener App
129.16
0.02%
-0.02
After Hours:
128.50
-0.66
-0.51%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $129.16, with a volume of 13.41M.
It is down -0.02% in the last 24 hours and down -3.24% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$129.18
Open:
$130.09
24h Volume:
13.41M
Relative Volume:
2.14
Market Cap:
$160.36B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
17.57
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
-3.92%
1M Performance:
-3.24%
6M Performance:
+6.55%
1Y Performance:
+16.93%
1-Day Range:
$128.92
$131.66
1-Week Range:
$127.07
$133.99
52-Week Range:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.16 | 160.39B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - Yahoo Finance
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo
Harvest Fund Management Co. Ltd Acquires 13,385 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Prudential PLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
GILD: Gilead Supports South Africa's Launch of Lenacapavir for H - GuruFocus
Gilead applauds efforts to launch lenacapavir for HIV prevention in South Africa - The Pharma Letter
Daiwa Securities Group Inc. Has $40.43 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cibc World Market Inc. Buys 97,779 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $2.38 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa - Business Wire
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
US FDA approves Gilead's drug for deadly liver infection - MSN
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline - TradingView
Gilead Sciences (GILD) Has an HIV-and-Oncology Bridge That Makes the Base Business Harder to Ignore - AlphaStreet
Gilead and Lakefront complete Ouro Medicines acquisition - Investing.com
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE - The Manila Times
Gilead’s Livdelzi approved by NICE for PBC - The Pharma Letter
TD Asset Management Inc Sells 67,251 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead eyes PBC expansion for Livdelzi on positive one-year data - Clinical Trials Arena
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
GILD Reports Positive Results From Late-Stage Liver Disease Study - Yahoo Finance
With Cencora pact, Gilead looks to grow CAR-T treatment center network - Fierce Pharma
IDEAL Data Expands Gilead’s Livdelzi Evidence Into Lower-ALP PBC Population - Citeline News & Insights
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Gilead Data On Livdelzi And Trodelvy Points To Broader Future Mix - simplywall.st
Marble Wealth LLC Acquires Shares of 9,588 Gilead Sciences, Inc. $GILD - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Asset Management Inc Buys 128,992 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Bio - GuruFocus
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 15,000 Shares - MarketBeat
Gilead (GILD) CEO Daniel O'Day sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome - Benzinga
Positive Phase III trial results for Gilead’s Livdelzi - The Pharma Letter
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population - Fierce Pharma
Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis - Insider Monkey
Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety - Yahoo Finance
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) - BioSpace
GILD Sees Positive Phase 3 Results for Livdelzi in Treating Prim - GuruFocus
Gilead reports positive Phase 3 trial results for PBC drug - Investing.com
Thompson Siegel & Walmsley LLC Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks - Barchart.com
Royal Bank Of Canada Upgrades Gilead Sciences (NASDAQ:GILD) to Moderate Buy - MarketBeat
BNP Paribas Has $11.36 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):